Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ISIS 2302 antisense inhibitor of ICAM-1 data

ISIP announced positive results of a Phase II trial of ISIS 2302. Based on these results, ISIP and partner Boehringer Ingelheim plan to begin a Phase III trial in April.

Trends in the three indices favored the treatment groups. At the end of one month of therapy, 47 percent of treated patients were in remission

Read the full 554 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers